Holen Sie sich die Stockscreener-App
22.35
5.78%
-1.37
Handel nachbörslich:
22.59
0.24
+1.07%
Schlusskurs vom Vortag:
$23.72
Offen:
$23.32
24-Stunden-Volumen:
3.13M
Relative Volume:
1.58
Marktkapitalisierung:
$4.22B
Einnahmen:
$219.12M
Nettoeinkommen (Verlust:
$-453.82M
KGV:
-5.7308
EPS:
-3.9
Netto-Cashflow:
$-419.68M
1W Leistung:
-14.43%
1M Leistung:
-14.10%
6M Leistung:
-25.72%
1J Leistung:
-23.59%
1-Tages-Spanne:
$22.10
$24.25
1-Wochen-Bereich:
$22.10
$26.62
52-Wochen-Spanne:
$21.62
$44.32
Bridgebio Pharma Inc Stock (BBIO) Company Profile
Firmenname
Bridgebio Pharma Inc
Sektor
Branche
Telefon
(650) 391-9740
Adresse
3160 PORTER DR., PALO ALTO, CA
Vergleichen Sie BBIO mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
| BBIO | 22.35 | 4.22B | 219.12M | -453.82M | -419.68M | -3.90 |
| VRTX | 467.01 | 119.87B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 762.00 | 83.27B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 567.90 | 33.96B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 232.27 | 30.18B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 101.87 | 24.42B | 3.30B | -501.07M | 1.03B | 11.54 |
Bridgebio Pharma Inc Stock (BBIO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-10-16 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-10-03 | Eingeleitet | Oppenheimer | Perform |
| 2024-09-04 | Eingeleitet | Piper Sandler | Overweight |
| 2024-03-21 | Fortgesetzt | Raymond James | Outperform |
| 2024-01-31 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2023-12-08 | Eingeleitet | Wells Fargo | Overweight |
| 2023-11-07 | Eingeleitet | Citigroup | Buy |
| 2023-10-24 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-07-18 | Herabstufung | Jefferies | Buy → Hold |
| 2023-04-19 | Eingeleitet | Evercore ISI | Outperform |
| 2023-02-06 | Eingeleitet | Cowen | Outperform |
| 2021-12-27 | Bestätigt | Mizuho | Buy |
| 2021-12-27 | Bestätigt | SVB Leerink | Outperform |
| 2021-09-10 | Hochstufung | BofA Securities | Neutral → Buy |
| 2021-05-21 | Eingeleitet | UBS | Buy |
| 2021-03-22 | Bestätigt | Goldman | Buy |
| 2021-02-22 | Fortgesetzt | JP Morgan | Overweight |
| 2021-02-09 | Fortgesetzt | Goldman | Buy |
| 2021-01-11 | Bestätigt | H.C. Wainwright | Buy |
| 2020-12-10 | Bestätigt | H.C. Wainwright | Buy |
| 2020-06-25 | Eingeleitet | BofA/Merrill | Neutral |
| 2020-05-19 | Eingeleitet | BTIG Research | Buy |
| 2020-04-13 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-02-19 | Eingeleitet | Mizuho | Buy |
| 2019-07-26 | Eingeleitet | Raymond James | Outperform |
| 2019-07-22 | Eingeleitet | BMO Capital Markets | Outperform |
| 2019-07-22 | Eingeleitet | Goldman | Buy |
| 2019-07-22 | Eingeleitet | JP Morgan | Overweight |
| 2019-07-22 | Eingeleitet | Jefferies | Buy |
| 2019-07-22 | Eingeleitet | Piper Jaffray | Overweight |
| 2019-07-22 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
Bridgebio Pharma Inc Aktie (BBIO) Neueste Nachrichten
BridgeBio Oncology Therapeutics (BBOT) Appoints Praveen Tipirneni, MD, to its Board of Directors as Non-Executive Director - BioSpace
Open-Label Extension Data Confirms Sustained Benefit of - GlobeNewswire
BridgeBio's Acoramidis Shows 36% Mortality Reduction in ATTR-CM Trial Extension | BBIO Stock News - StockTitan
BridgeBio Pharma Announces Publication in the New England Journal of Medicine of Phase 2 PROPEL - The Bakersfield Californian
BridgeBio Pharma Announces Publication in the New England - GlobeNewswire
Shareholders in BridgeBio Pharma (NASDAQ:BBIO) have lost 44%, as stock drops 12% this past week - Simply Wall St
BridgeBio Pharma, Inc. (NASDAQ:BBIO) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Scotiabank Issues Positive Forecast for BridgeBio Pharma (NASDAQ:BBIO) Stock Price - MarketBeat
Leerink Partnrs Expects Weaker Earnings for BridgeBio Pharma - MarketBeat
BridgeBio: 2 Weeks Until Major Drug Approval Catalyst — A Buy, With Caveats (BBIO) - Seeking Alpha
Leerink Partnrs Has Negative Outlook of BBIO FY2028 Earnings - MarketBeat
BridgeBio Pharma Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance
BridgeBio Pharma Reports Quarterly Loss Amid Restructuring - TipRanks
No-Moat BridgeBio's Valuation Driven by Pending Approval of Acoramidis; Positive Long-Term Outlook - Morningstar
BridgeBio Pharma Inc Reports Q3 2024 Revenue of $2.7 Million, Mi - GuruFocus.com
BridgeBio Pharma (BBIO) Reports Q3 Loss, Lags Revenue Estimates - MSN
BridgeBio Pharma earnings beat by $0.13, revenue topped estimates - Investing.com UK
BridgeBio Pharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Achondroplasia Market to Show Remarkable Growth Trends from 2024 to 2034, DelveInsight Reports | Sanofi, Changchun GeneScience Pharma, QED Therapeutics, Inc., BridgeBio, QED Therapeutics , Ribomic - Barchart
Achondroplasia Market to Show Remarkable Growth Trends from - openPR
BridgeBio Pharma: Q3 Earnings Snapshot - San Antonio Express-News
BridgeBio Pharma Reports Third Quarter 2024 Financial Results and Business Update - The Manila Times
BridgeBio's Acoramidis Nears FDA Approval; $500M Milestone Payment Awaits | BBIO Stock News - StockTitan
WCM Investment Management LLC Purchases 86,987 Shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO) - MarketBeat
Trend Tracker for (BBIO) - Stock Traders Daily
BridgeBio Announces Publication of Case Study Exploring - GlobeNewswire
BridgeBio Dives on Revealing Case Study - Baystreet.ca
BridgeBio's Portfolio Theory Innovation Reshapes Drug Development Strategy | BBIO Stock News - StockTitan
Achondroplasia Market Forecasted to Surge in Coming Years, - openPR
BridgeBio Pharma, Inc. (NASDAQ:BBIO) Position Increased by Emerald Advisers LLC - MarketBeat
BridgeBio Pharma (NASDAQ:BBIO) Shares Up 8.3%Still a Buy? - MarketBeat
BridgeBio Pharma (BBIO) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release - Yahoo Finance
(BBIO) Proactive Strategies - Stock Traders Daily
Seven PDUFA dates on FDA’s November calendar - BioCentury
BridgeBio Oncology Therapeutics (BBOT) Announces First Patient Dosed with First-in-Class BBO-10203, a RAS:PI3Kα Breaker, in the Phase 1 BREAKER-101 Trial for Advanced Solid Tumors - Yahoo Finance
Biotech Stocks Facing FDA Decision In November 2024 - RTTNews
Citigroup Initiates Coverage of BridgeBio Pharma (BBIO) with Buy Recommendation - MSN
BridgeBio Pharma (NASDAQ:BBIO) Earns Buy Rating from HC Wainwright - MarketBeat
Gene therapy shows promise in Canavan disease trial By Investing.com - Investing.com Australia
Citi reiterates Buy rating on BridgeBio shares, cites clinical results By Investing.com - Investing.com Canada
Gene therapy shows promise in Canavan disease trial - Investing.com
BridgeBio Shares Positive Data from High Dose Cohort of Phase 1/2 CANaspire Study of Gene Therapy BBP-812 for Canavan Disease at ESGCT 2024 - GlobeNewswire
BridgeBio Shares Positive Data from High Dose Cohort of Phase 1/2 CANaspire Study of Gene - The Bakersfield Californian
Investors in BridgeBio Pharma (NASDAQ:BBIO) have unfortunately lost 49% over the last three years - Yahoo Finance
BridgeBio Pharma, Inc. (NASDAQ:BBIO) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Objective long/short (BBIO) Report - Stock Traders Daily
Scotiabank Initiates Coverage of BridgeBio Pharma (BBIO) with Sector Outperform Recommendation - MSN
BridgeBio Pharma (NASDAQ:BBIO) Price Target Cut to $46.00 by Analysts at Leerink Partners - MarketBeat
Equities Analysts Offer Predictions for BridgeBio Pharma, Inc.'s Q3 2024 Earnings (NASDAQ:BBIO) - MarketBeat
Leerink Partnrs Issues Pessimistic Outlook for BBIO Earnings - MarketBeat
BridgeBio Pharma (NASDAQ:BBIO) Now Covered by Analysts at Scotiabank - MarketBeat
Finanzdaten der Bridgebio Pharma Inc-Aktie (BBIO)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.66%
1.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):